Two presentations at LINC 2022 focus on the performance of BIOTRONIK’s drug-coated balloon as a standalone therapy or combined with selective stenting following suboptimal angioplasty in challenging femoropopliteal lesions
BIOTRONIK announced the presentation of two studies on the performance of its drug-coated balloon catheter Passeo®-18 Lux® at this year’s LINC congress in Leipzig, Germany. The BIO REACT study was designed to better understand when and where a stent is needed following drug-coated balloon for the treatment of femoropopliteal artery lesions in patients with peripheral artery disease (PAD).1 Dr. Michael Lichtenberg, Chief Physician, Arnsberg Vascular Center at Karolinen Hospital, Germany, revealed the 12-month outcomes of this pilot study. While the use of intraoperative duplex-ultrasound in this small cohort didn’t improve the identification of flow-limiting dissections, the presented data showed that BIOTRONIK REsponse Adapted Combination Therapy—combining Passeo-18 Lux DCB with Pulsar-18 T3 thin-strut stents when and where needed—is a safe and effective treatment of femoropopliteal lesions, while leaving less metal behind.